RELIEF THERAPEUTICS N overview

GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update. In his annual letter to shareholders, Dr. Raghuram Selvaraju, chairman of the board of directors, emphasized the Company's operational achievements, pipeline...

Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update 10-Apr-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update GENEVA (APR. 10, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief), a...

GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF , RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussions regarding a potential merger with Renexxion, Inc. (Renexxion) have been terminated. After signing a non-binding letter of intent in November 2024, both companies engaged in discussions to...

Relief Therapeutics Holding SA / Key word(s): Merger Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion 06-March-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion GENEVA (March 6, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief, or the Company), a...

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application titled "Therapeutic Uses...

Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 11.02.2025 / 07:00 CET/CEST Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA (FEB. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief, or the Company), a biopharmaceutical company...

Sale of GOLIKE ® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the sale of its intellectual property and commercialization...

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US 22-Jan-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE ® Rights ex-US Sale of GOLIKE ® Rights Outside the U.S. to Nutrisens Relief to Focus on R&D of Pipeline Assets and Licensing...